Peter Lackner, Andrea Part, Christoph Burger, Anelia Dietmann, Gregor Broessner, Raimund Helbok, Markus Reindl, Erich Schmutzhard, Ronny Beer
BACKGROUND: Cerebral malaria (CM) is associated with high mortality and morbidity caused by a high rate of transient or persistent neurological sequelae. Studies on immunomodulatory and neuroprotective drugs as ancillary treatment in murine CM indicate promising potential. The current study was conducted to evaluate the efficacy of glatiramer acetate (GA), an immunomodulatory drug approved for the treatment of relapsing remitting multiple sclerosis, in preventing the death of C57Bl/6J mice infected with Plasmodium berghei ANKA...
February 27, 2009: Malaria Journal